Remdesivir drug to cost $2,340 per patient

Gilead Sciences priced its Covid-19 drug candidate remdesivir at $2,340 for a five-day treatment in the US and some other developed countries, it said on Monday cited by Reuters. The price for a single vial was put at $390. This is below the $5,080 per course recommendation by US drug pricing research group, the Institute for Clinical and Economic Review, last week.

Gilead has entered into an agreement with the US Department of Health and Human Services (HHS), with the agency and states set to manage allocation to hospitals until the end of September. HHS has secured more than 500,000 treatment courses of the drug for American hospitals through September, the agency said on Monday.

This represents 100% of Gilead’s projected production for July of 94,200 treatment courses, 90% of production in August and September, in addition to an allocation for clinical trials, HHS said. After this period, once supplies are less constrained, HHS will stop managing the allocation, Gilead said.

Remdesivir’s price has been a topic of intense debate since the US Food and Drug Administration approved its emergency use in some Covid-19 patients in May. Experts have said that Gilead would need to avoid the appearance of taking advantage of a health crisis for profits. Last week the drug was approved by EU Medicines Agency as well.

More on this subject: Coronavirus

Similar articles